MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/noajnl/vdaf046

Медицинская библиотека · Neuro-oncology advances · 2025

Cerebrospinal fluid protein biomarkers are associated with response to multiagent intraventricular chemotherapy in patients with CNS lymphoma.

Aastha Aastha, Wilding Hannah, Mikolajewicz Nicholas, Khan Shahbaz, Ignatchenko Vladimir, De Macedo Filho Leonardo Jose Monteiro, Bhanja Debarati, Remite-Berthet Gabriela, Heebner Madison, Glantz Michael, Mansouri Alireza, Kislinger Thomas

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Central nervous system lymphoma (CNSL), is a rare subtype of non-Hodgkin lymphoma, primarily affecting the brain and spinal cord. Most therapeutic systemic agents have limited penetration of the blood-brain and blood-cerebrospinal fluid (CSF) barrier, with the latter potentially promoting a treatment "sanctuary" for cancer cells. Evaluation of occult disease, particularly in the CSF, is challenging. In limited clinical experience, the addition of multiagent intraventricular chemotherapy (MAIVC), delivered through intracranially implanted CSF reservoirs, to systemic therapy has demonstrated encouraging outcomes, enhancing both progression-free survival and overall survival. However, given the potential morbidity associated with MAIVC, identification of minimally invasive biomarkers for guiding patient selection and management is necessary. Leveraging the longitudinal, large volume of CSF, the objective of this study was to identify CSF-based proteomic biomarkers that can serve as reliable indicators of CSF clearance in response to MAIVC and CNSL treatment outcome.

METHODS

One hundred fifteen CSF samples from 59 CNSL patients receiving MAIVC were profiled using a high-throughput protocol coupled with mass-spectrometry that only requires 30 μL of CSF.

RESULTS

More than 2000 unique proteins were detected using shotgun proteomics. Cerebrospinal fluid proteomics revealed key proteins (SGCE, LCP1, AGRN, OLFML3, and HRSP12) distinguishing early from never responders to MAIVC, with area under the receiver operating characteristic (AUROC) 0.86 (95% CI: 0.696-1). By integrating tumor volume from brain MRI scans with proteomic data, we identified potential intraventricular tumor burden markers for CNSL management, in particular LCP1.

CONCLUSIONS

The study identified CSF-based proteomic biomarkers, particularly LCP1, that can classify MAIVC response and indicate tumor burden in CNSL patients.

Для цитирования: Aastha Aastha, Wilding Hannah, Mikolajewicz Nicholas, Khan Shahbaz, Ignatchenko Vladimir, De Macedo Filho Leonardo Jose Monteiro, Bhanja Debarati, Remite-Berthet Gabriela, Heebner Madison, Glantz Michael, Mansouri Alireza, Kislinger Thomas. Cerebrospinal fluid protein biomarkers are associated with response to multiagent intraventricular chemotherapy in patients with CNS lymphoma.. Neuro-oncology advances. 2025. DOI: 10.1093/noajnl/vdaf046.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.